HC Wainwright Reiterates Buy Rating for Senseonics (NYSE:SENS)

Senseonics (NYSE:SENS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 225.63% from the company’s previous close.

Separately, StockNews.com began coverage on shares of Senseonics in a research note on Thursday, December 26th. They issued a “sell” rating for the company.

Senseonics Stock Performance

Shares of NYSE SENS opened at $0.61 on Wednesday. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. Senseonics has a one year low of $0.25 and a one year high of $1.40. The business’s 50-day moving average price is $0.86 and its two-hundred day moving average price is $0.53. The company has a market capitalization of $365.65 million, a P/E ratio of -4.72 and a beta of 1.17.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same period in the prior year, the firm posted ($0.07) earnings per share. Analysts anticipate that Senseonics will post -0.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Senseonics news, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now owns 2,478,844 shares in the company, valued at $941,960.72. This trade represents a 5.31 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, with a total value of $97,650.00. Following the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. First Light Asset Management LLC acquired a new position in Senseonics during the 4th quarter valued at $3,366,000. Geode Capital Management LLC increased its holdings in shares of Senseonics by 9.7% during the 4th quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company’s stock worth $3,354,000 after purchasing an additional 566,704 shares during the period. Jane Street Group LLC lifted its stake in shares of Senseonics by 6,694.1% in the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company’s stock valued at $3,203,000 after buying an additional 6,028,726 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Senseonics by 9.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company’s stock valued at $1,748,000 after buying an additional 274,842 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Senseonics during the fourth quarter worth about $720,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.